New drug duo shows promise for rare blood cancer

NCT ID NCT05734495

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two oral drugs, pirtobrutinib and venetoclax, in 46 people with Waldenström macroglobulinemia who have already had at least one prior treatment. The goal is to see if the combination can shrink the cancer and improve response rates. Researchers are also tracking how long the benefits last and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pirtobrutinib and Venetoclax (two oral drugs)
What this could lead to: If it works, this could offer a new treatment option for people with Waldenström macroglobulinemia who have already tried other therapies.
What could go wrong: This is a small, early-phase study (46 people) with no control group. The combination may not work better than existing treatments and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

WALDENSTROM MACROGLOBULINEMIA

Contacts and locations

Locations

Beth Israel Deaconness Medical

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.